2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

pancreatic B cell

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

3

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164546
    WB436B

    		STAT Apoptosis Cancer
    WB436B is a highly selective STAT3 inhibitor. WB436B can selectively inhibit STAT3-Tyr705 phosphorylation and the expression of STAT3 target genes, showing cytotoxic effects on pancreatic cancer cells and inducing apoptosis. WB436B can suppress tumor growth and metastasis in pancreatic cancer mouse models, extending the survival of tumor-bearing mice .
    WB436B
  • HY-144310
    DX3-213B

    		Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor (IC50=3.6 nM). DX3-213B impairs ATP generation (IC50=11 nM), and blocks MIA PaCa-2 cell growth (GI50=11 nM). DX3-213B is used for the research of the pancreatic cancer .
    DX3-213B
  • HY-164684
    Dichlorobenzamil

    3',4'-Dichlorobenzamil; L-594881

    		 Calcium Channel Sodium Channel Na+/Ca2+ Exchanger Others
    Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) is an effective Na/Ca exchange inhibitor. Dichlorobenzamil significantly inhibits 45Ca uptake mediated by reverse Na/Ca exchange in pancreatic islet cells (IC50 = 18 μM). Dichlorobenzamil can also block K + channels and voltage-sensitive Ca 2+ channels .
    Dichlorobenzamil
  • HY-N12834
    Ecdysoside B

    		Others Inflammation/Immunology Cancer
    Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .
    Ecdysoside B
  • HY-161320
    EGFR-IN-105

    		EGFR Apoptosis Cancer
    EGFR-IN-105 (Compound 5b) is an EGFR2 inhibitor with an IC50 value of 0.68 μM. EGFR-IN-105 exhibits anticancer activity and can induce apoptosis in cancer cells, which is used in the research of pancreatic cancer .
    EGFR-IN-105
  • HY-P991317
    BTH1704

    		Mucin Cancer
    BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
    BTH1704
  • HY-159496
    Dyrk1A-IN-10

    		DYRK Metabolic Disease
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
    Dyrk1A-IN-10
  • HY-B0311S1
    Carbidopa-d3-1

    (S)-(-)-Carbidopa-d3

    		 Aryl Hydrocarbon Receptor Isotope-Labeled Compounds Neurological Disease
    Carbidopa-d3-1 is the deuterium labeled Carbidopa (HY-B0311). Carbidopa, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth .
    Carbidopa-d3-1
  • HY-159893
    SMO-IN-5

    		Smo Hedgehog Apoptosis Cancer
    SMO-IN-5 ((Compound 25(B31)) is a potent and competitive inhibitor of smoothened (SMO) that can inhibit Hedgehog (Hh) signaling. SMO-IN-5 interacts with Smo through hydrogen bonds, hydrophobic interactions, and electrostatic forces. SMO-IN-5 inhibits PC cell proliferation, migration, and induces apoptosis by suppressing Gli1 expression. SMO-IN-5 exhibits antitumor activity in pancreatic cancer. .
    SMO-IN-5
  • HY-129085
    5-Methyl cromolyn disodium

    C5OH

    		 Drug Derivative Apoptosis NF-κB Cancer
    5-Methyl cromolyn (C5OH) disodium, an analog of Cromolyn (HY-B1619), is a S100P inhibitor. 5-Methyl cromolyn disodium inhibits the binding of S100P to its receptor RAGE, NF-κB activity and cell proliferation, and promotes Gemcitabine (HY-17026)-induced apoptosis. 5-Methyl cromolyn disodium reduces tumor growth and metastasis, and prolongs survival in mouse models of syngeneic PDAC. 5-Methyl cromolyn disodium can be used for pancreatic cancer like pancreatic ductal adenocarcinoma (PDAC) research .
    5-Methyl cromolyn disodium
  • HY-113037S1
    Farnesyl pyrophosphate-d3

    Farnesyl diphosphate-d3

    		 TRP Channel Isotope-Labeled Compounds Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate-d3 (Farnesyl diphosphate-d3) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d3
  • HY-113037AS
    Farnesyl pyrophosphate-d6

    Farnesyl diphosphate-d6

    		 Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate-d6 (Farnesyl diphosphate-d6) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d6
  • HY-124295
    Imofinostat

    ABT-301; MPT0E028; TMU-C-0012

    		 HDAC Akt Apoptosis Inflammation/Immunology Cancer
    Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 ​​μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .
    Imofinostat
  • HY-N0058
    4,5-Dicaffeoylquinic acid
    Maximum Cited Publications
    9 Publications Verification

    Isochlorogenic acid C

    		 HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid
  • HY-13072
    Cenisertib
    1 Publications Verification

    AS-703569; R-763

    		 Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib
  • HY-167924
    Ono 3307 free base

    		Kallikrein Thrombin Ser/Thr Protease Inflammation/Immunology
    Ono 3307 Free base is a novel synthetic protease inhibitor that exhibits protective effects against acute pancreatitis by preventing hyperamylasemia and pancreatic edema. Ono 3307 Free base also inhibits the redistribution of lysosomal enzymes in acinar cells and mitigates lactic dehydrogenase discharge. Ono 3307 Free base effectively reduces cathepsin B leakage from lysosomes in a dose-dependent manner. Ono 3307 Free base is able to target trypsin (Ki=48 nM), thrombin (Ki=0.18 μM), plasma kallikrein (Ki=0.29 μM), plasmin (Ki=0.31 μM), pancreatic kallikrein (Ki=3.6 μM), and chymotrypsin (Ki=47 μM).
    Ono 3307 free base
  • HY-13072B
    Cenisertib benzoate

    AS-703569 benzoate; R-763 benzoate

    		 Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib benzoate
  • HY-W777434
    Mitiglinide calcium hydrate-d8

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate)-d8 is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate-d8
  • HY-120561
    PC-046

    		Trk Receptor IRAK Pim Apoptosis Cancer
    PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .
    PC-046
  • HY-117085
    Lobaric acid

    		Phosphatase TMV Lipoxygenase Cancer
    Lobaric acid is a depsipeptide metabolite isolated from Stereocaulon lichen with antioxidant, antiproliferative, antiviral and enzyme inhibitory activities. Lobaric acid scavenges superoxide free radicals (IC50=97.9 μM) and inhibits cancer cell proliferation (EC50 of 15.2-63.9 μg/mL against leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic and lung cancer cell lines). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50=0.87 μM for human recombinant enzyme) and 12(S)-HETE produced by 12(S)-lipoxygenase (IC50=28.5 μM). Lobaric acid (250 μM) also reduced pathological changes in tobacco leaves infected with tobacco mosaic virus (TMV).
    Lobaric acid
  • HY-13072R
    Cenisertib (Standard)

    		Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib (Standard)
  • HY-168718
    FAK-IN-22

    		FAK JAK Aurora Kinase PI3K Akt Apoptosis Cancer
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway .
    FAK-IN-22
  • HY-177345
    SV119

    		Sigma Receptor Apoptosis Caspase Cancer
    SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer .
    SV119
  • HY-P2055
    A-57696

    		Endogenous Metabolite Endocrinology
    A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .
    A-57696
  • HY-175025
    CH091138

    		PROTACs Ras Apoptosis Cancer
    CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRAS WT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer. (Pink: KRASG12D ligand (HY-175144); Blue: VHL E3 ligase ligand (HY-138678); Black: Linker; VHL E3 ligase ligand + Linker (HY-136006B)) .
    CH091138
  • HY-N0058R
    4,5-Dicaffeoylquinic acid (Standard)

    Isochlorogenic acid C (Standard)

    		 Reference Standards HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid (Standard)
  • HY-B0984A
    Fendiline
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline
  • HY-B0984
    Fendiline hydrochloride
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride
  • HY-160777
    VNPP433-3β

    Galeterone 3β-imidazole

    		 Molecular Glues Androgen Receptor MNK Apoptosis Cancer
    VNPP433-3β (Galeterone 3β-imidazole) is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2.VNPP433-3β induces cell apoptosis. VNPP433-3β inhibits proliferation of cancer cell LNCaP, C4-2B and CWR22Rv1 with GI50 of 0.2, 0.3 and 0.31 μM. VNPP433-3β exhibits good pharmacokinetic characters in CD-1 mouse and inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
    VNPP433-3β
  • HY-B0984R
    Fendiline hydrochloride (Standard)

    		Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride (Standard)
  • HY-P990237
    Anti-Mouse ICOS Antibody (7E.17G9)

    		CD28 Inflammation/Immunology Cancer
    Anti-Mouse ICOS Antibody (7E.17G9) is an anti-mouse ICOS IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
    Anti-Mouse ICOS Antibody (7E.17G9)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: